S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
S&P 500   4,443.11 (-0.28%)
DOW   34,869.37 (+0.21%)
QQQ   370.35 (-0.80%)
AAPL   145.37 (-1.05%)
MSFT   294.17 (-1.73%)
FB   353.58 (+0.18%)
GOOGL   2,821.44 (-0.80%)
TSLA   791.36 (+2.19%)
AMZN   3,405.80 (-0.58%)
NVDA   216.60 (-1.91%)
BABA   150.18 (+3.52%)
NIO   36.77 (+3.93%)
CGC   14.71 (+5.75%)
GE   105.35 (+1.49%)
MU   75.18 (+1.53%)
AMD   108.16 (+2.23%)
T   27.40 (+1.00%)
F   14.16 (+2.76%)
ACB   6.39 (+7.39%)
DIS   178.26 (+1.28%)
PFE   43.57 (-0.84%)
BA   224.16 (+1.25%)
AMC   39.30 (-1.77%)
ASX:PXS

Pharmaxis Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume721,139 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive PXS News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter.


About Pharmaxis

Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$23.58 million
Book Value
A$0.01 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.10 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Pharmaxis (ASX:PXS) Frequently Asked Questions

What stocks does MarketBeat like better than Pharmaxis?

Wall Street analysts have given Pharmaxis a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Pharmaxis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Pharmaxis' earnings last quarter?

Pharmaxis Ltd (ASX:PXS) posted its quarterly earnings data on Thursday, February, 14th. The company reported ($0.03) earnings per share for the quarter.
View Pharmaxis' earnings history
.

Who are Pharmaxis' key executives?

Pharmaxis' management team includes the following people:
  • Mr. Gary Jonathan Phillips, CEO, MD & Director (Age 60, Pay $484.86k)
  • Mr. David Morris McGarvey BA, CA, CPA, CFO & Company Sec. (Age 65, Pay $400.08k)
  • Dr. Wolfgang G. Jarolimek Ph.D., B.Sc. Ph.D., Head of Drug Discovery (Age 57, Pay $393.82k)
  • Ms. Kristen Morgan B.Sc., BSc, PGDipBusAdmin, MMedSc, Alliance Management - Head of Medical & Regulatory Affairs (Age 49, Pay $217.93k)
  • Dr. Brett Charlton Ph.D., MBBS Ph.D., Medical Director (Age 65, Pay $393.67k)
  • Mr. Cameron David Billingsley, Gen. Counsel (Age 44)
  • Dr. Dieter Hamprecht, Head of Chemistry for Drug Discovery

What other stocks do shareholders of Pharmaxis own?

What is Pharmaxis' stock symbol?

Pharmaxis trades on the ASX under the ticker symbol "PXS."

How much money does Pharmaxis make?

Pharmaxis has a market capitalization of $0.00 and generates $23.58 million in revenue each year.

How many employees does Pharmaxis have?

Pharmaxis employs 69 workers across the globe.

What is Pharmaxis' official website?

The official website for Pharmaxis is www.pharmaxis.com.au.

Where are Pharmaxis' headquarters?

How can I contact Pharmaxis?

Pharmaxis' mailing address is 20 Rodborough Rd, FRENCHS FOREST, NSW 2086, Australia. The company can be reached via phone at +61-2-94547200.


This page was last updated on 9/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.